{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:51:49Z","timestamp":1792644709694,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.cyto.2017.12.026","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T19:07:44Z","timestamp":1515438464000},"page":"63-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation"],"prefix":"10.1016","volume":"103","author":[{"given":"Adina Elena","family":"Stanciu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu Gabriel","family":"Vatasescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel Marian","family":"Stanciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafija","family":"Serdarevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dorobantu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2017.12.026_b0005","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ijcard.2012.12.093","article-title":"Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century","volume":"167","author":"Ball","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.cyto.2017.12.026_b0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.tcm.2016.06.007","article-title":"Update on atrial fibrillation","volume":"27","author":"Khaji","year":"2017","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.cyto.2017.12.026_b0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cyto.2017.12.026_b0020","first-page":"2071","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cyto.2017.12.026_b0025","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"Kirchhof","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.cyto.2017.12.026_b0030","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/CIRCEP.111.966523","article-title":"Acute pulmonary vein isolation is achieved by a combination of reversible and irreversible atrial injury after catheter ablation: evidence from magnetic resonance imaging","volume":"5","author":"Arujuna","year":"2012","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"10.1016\/j.cyto.2017.12.026_b0035","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1161\/01.CIR.0000103131.70301.4F","article-title":"Inflammation as a risk factor for atrial fibrillation","volume":"108","author":"Aviles","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cyto.2017.12.026_b0040","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.amjcard.2004.12.016","article-title":"Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation","volume":"95","author":"Roldan","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.cyto.2017.12.026_b0045","doi-asserted-by":"crossref","first-page":"e0155275","DOI":"10.1371\/journal.pone.0155275","article-title":"Association of plasma transforming growth factor-\u03b21 levels and the risk of atrial fibrillation: a meta-analysis","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2017.12.026_b0050","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1016\/j.jacc.2014.04.020","article-title":"Differentiating paroxysmal from persistent atrial fibrillation: long-term electrocardiographic monitoring is mightier than the clinician","volume":"63","author":"Mittal","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cyto.2017.12.026_b0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ancard.2014.12.004","article-title":"MMP-9 in atrial remodeling in patients with atrial fibrillation","volume":"64","author":"Lewkowicz","year":"2015","journal-title":"Ann. Cardiol. Angeiol. (Paris)"},{"key":"10.1016\/j.cyto.2017.12.026_b0060","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3109\/00365513.2015.1057895","article-title":"IL-4, IL-10 and high sensitivity-CRP as potential serum biomarkers of persistent\/recurrent disease in papillary thyroid carcinoma with\/without Hashimoto's thyroiditis","volume":"75","author":"Stanciu","year":"2015","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.cyto.2017.12.026_b0065","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1080\/00365513.2016.1230883","article-title":"Effects of thyroid hormone withdrawal on natriuretic peptides during radioactive iodine therapy in female patients with differentiated thyroid cancer","volume":"76","author":"Stanciu","year":"2016","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.cyto.2017.12.026_b0070","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/heartjnl-2016-310236","article-title":"N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation","volume":"103","author":"Svennberg","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.cyto.2017.12.026_b0075","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ahj.2004.01.026","article-title":"Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation","volume":"148","author":"Conway","year":"2004","journal-title":"Am. Heart J."},{"key":"10.1016\/j.cyto.2017.12.026_b0080","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijcard.2008.04.087","article-title":"Oxidative stress and inflammatory process in patients with atrial fibrillation: the role of left atrium distension","volume":"136","author":"Tousoulis","year":"2009","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.cyto.2017.12.026_b0085","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/europace\/eun111","article-title":"Source of inflammatory markers in patients with atrial fibrillation","volume":"10","author":"Liuba","year":"2008","journal-title":"Europace"},{"key":"10.1016\/j.cyto.2017.12.026_b0090","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/europace\/eur418","article-title":"Increased intracardiac vascular endothelial growth factor levels in patients with paroxysmal, but not persistent atrial fibrillation","volume":"14","author":"Scridon","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.cyto.2017.12.026_b0095","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jacc.2015.06.1313","article-title":"Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications","volume":"66","author":"Dzeshka","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cyto.2017.12.026_b0100","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.7754\/Clin.Lab.2016.160139","article-title":"Serum level of matrix metalloproteinase-9 in patients with head and neck squamous cell carcinoma","volume":"62","author":"Stanciu","year":"2016","journal-title":"Clin. Lab."},{"key":"10.1016\/j.cyto.2017.12.026_b0105","series-title":"Role of the Clinical Cardiac Electrophysiologist in the Management of Congestive Heart Failure","first-page":"141","article-title":"Impact of thyroid disease on heart failure","author":"Stanciu","year":"2017"},{"key":"10.1016\/j.cyto.2017.12.026_b0110","doi-asserted-by":"crossref","first-page":"e59052","DOI":"10.1371\/journal.pone.0059052","article-title":"Novel association between plasma matrix metalloproteinase-9 and risk of incident atrial fibrillation in a case-cohort study: the Atherosclerosis Risk in Communities study","volume":"8","author":"Huxley","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2017.12.026_b0115","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/0300060513488514","article-title":"Changes in matrix metalloproteinase-9 levels during progression of atrial fibrillation","volume":"42","author":"Li","year":"2014","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.cyto.2017.12.026_b0120","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ijcard.2009.03.110","article-title":"Atrial fibrosis and atrial fibrillation: the role of the TGF-\u03b21 signaling pathway","volume":"143","author":"Gramley","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.cyto.2017.12.026_b0125","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00392-010-0248-1","article-title":"Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure","volume":"100","author":"Behnes","year":"2011","journal-title":"Clin. Res. Cardiol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466617303976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466617303976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T16:53:50Z","timestamp":1535129630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466617303976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":25,"alternative-id":["S1043466617303976"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2017.12.026","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2017.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}